User profiles for L. P. James

Laura P James

University of Arkansas for Medical Sciences; Arkansas Children's Hospital
Verified email at uams.edu
Cited by 11724

The Myc/Max/Mad network and the transcriptional control of cell behavior

C Grandori, SM Cowley, LP James… - Annual review of cell …, 2000 - annualreviews.org
… Indeed, in vitro selection experiments with randomized oligonucleotides demonstrate that
full-length Mad selects the same consensus E-box and flanking sequences as Myc (LP James, …

Acetaminophen-induced hepatotoxicity

LP James, PR Mayeux, JA Hinson - Drug metabolism and disposition, 2003 - ASPET
The analgesic acetaminophen causes a potentially fatal, hepatic centrilobular necrosis when
taken in overdose. The initial phases of toxicity were described in Dr. Gillette's laboratory in …

Mechanisms of acetaminophen-induced liver necrosis

JA Hinson, DW Roberts, LP James - Adverse drug reactions, 2010 - Springer
… Subsequent work by James reported no difference in toxicity between TNFR1 knockout
mice and wild-type mice (James et al. 2005). Conflicting data from these studies, compared to …

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

…, GJ Riely, EH Tan, T Seto, LP James… - The Lancet …, 2018 - thelancet.com
Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was …

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

…, JF Gainor, M Johnson, J Dietrich, LP James… - The Lancet …, 2017 - thelancet.com
Background Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene
1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to …

[HTML][HTML] Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

…, RL Frias, KR Schultz, J Logan, LP James… - … England Journal of …, 2016 - Mass Medical Soc
<p id="p001">In a patient who had metastatic anaplastic lymphoma kinase (<italic>ALK</italic>)-rearranged
lung cancer, resistance to crizotinib developed because of a mutation in the …

Acetaminophen‐induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition

…, AB Reid, SS McCullough, LP James - Drug metabolism …, 2004 - Taylor & Francis
Large doses of the analgesic acetaminophen cause centrilobular hepatic necrosis in man
and in experimental animals. It has been previously shown that acetaminophen is …

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non–small cell lung cancer

B Zhao, LP James, CS Moskowitz, P Guo, MS Ginsberg… - Radiology, 2009 - pubs.rsna.org
Purpose To evaluate the variability of tumor unidimensional, bidimensional, and volumetric
measurements on same-day repeat computed tomographic (CT) scans in patients with non–…

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

…, W Zhao, L Tye, P Stephenson, KD Wilner, LP James… - 2014 - ascopubs.org
8001 Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive
to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the …

Measurement of serum acetaminophen–protein adducts in patients with acute liver failure

TJ Davern II, LP James, JA Hinson, J Polson… - Gastroenterology, 2006 - Elsevier
Background & Aims: Acetaminophen toxicity is the most common cause of acute liver failure
(ALF) in the United States and Great Britain, but may be underrecognized in certain settings. …